Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 04, 2019 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Reports Data from Part A of the Ongoing Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients at ASCO 2019

Well tolerated at all doses with no safety signalsThree patients in high dose (10 µg) cohort showed evidence of stable disease by MRI10 µg dose selected for Part B of the study, which is expected...